Fortuna Fix announces Series B financing

Fortuna Fix, a private, UK and Canada-based clinical-stage regenerative medicine company is aiming to be the first to bring to the clinic a patient's own neural stem cells (autologous) produced by direct reprogramming (drNPCs) to replace lost neuronal tissue in neurodegeneration and neurotrauma.

Fortuna today revealed the closing of its $25 million Series B financing. The proceeds will enable the company to conduct Phase I/IIa clinical trials in Parkinson’s disease and spinal cord Injury. Amgen Ventures and other new investors join existing shareholders including Salamander Invest to support the development of Fortuna’s lead programs and its neuro-regenerative technology platforms. In addition to clinical development, the financing will enable further expansion of Fortuna’s automated robotic manufacturing capabilities.